Ticagrelore Alone Post PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5400 participants.

Also called NCT06509893

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 5,400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06509893
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Iran (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06509893. Randomized; triple masking; primary purpose treatment. Start 2024-08-01 (actual); primary completion 2025-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelore Alone Post PCI
Acronym
TICALONE
Intervention (Drug)
aspirin 80 mg and clopidogrel 75 mg daily
Intervention (Drug)
Ticagrelor 90 MG
Lead sponsor
Shiraz University of Medical Sciences (class: other)

Record details

Record id
cardio:ct-nct06509893
Content hash
c8acef048cfa7ac9ddc73e1e895ff1281d22c766e9cf852a8ecd7100a261c983